Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Small Cell Lung Carcinoma 31Burkitt Lymphoma 12Recurrence 11Lung Neoplasms 11Leukemia, Myeloid, Acute 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 8Hodgkin Disease 8Carcinoma, Non-Small-Cell Lung 7Neuroblastoma 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Lymphoma, B-Cell 4Leukemia 4Wilms Tumor 3Sarcoma, Ewing 3Plasmablastic Lymphoma 3Neoplasms, Germ Cell and Embryonal 3Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Immunoblastic Lymphadenopathy 3Ganglioneuroblastoma 3Waldenstrom Macroglobulinemia 2

Interventions

Rituximab 2Radiotherapy, Intensity-Modulated 2pomalidomide 1dehydroftorafur 1Watchful Waiting 1Vincristine 1Taxes 1Prednisone 1Platinum 1Phantoms, Imaging 1Paclitaxel 1Nivolumab 1Matrix-M 1Magnetic Resonance Spectroscopy 1Gemcitabine 1Fluorouracil 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Cisplatin 1Blood Specimen Collection 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epstein-Barr Virus Infections × Etoposide × 90 days × Clear all
NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡